TCM
NVO

TimesSquare Capital Management’s Novo Nordisk NVO Stock Holding History

TimesSquare Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,310
Closed -$860K – 168
2023
Q4 		$860K Buy
8,310
+800
+11% +$79.1K 0.01% 156
2023
Q3 		$683K Sell
7,510
-10,060
-57% -$886K 0.01% 155
2023
Q2 		$1.42M Sell
17,570
-3,160
-15% -$258K 0.02% 166
2023
Q1 		$1.65M Buy
20,730
+4,030
+24% +$286K 0.02% 167
2022
Q4 		$1.13M Sell
16,700
-8,540
-34% -$501K 0.02% 171
2022
Q3 		$1.26M Buy
+25,240
New +$1.35M 0.02% 183

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TimesSquare Capital Management's NVO Position: Q1 2024 in Review

TimesSquare Capital Management sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 8,310 shares — an estimated $860K sold.

TimesSquare Capital Management first reported a position in NVO in Q3 2022 and held it in 6 quarters. The position peaked at $1.65M in Q1 2023. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

  • TimesSquare Capital Management reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
  • TimesSquare Capital Management sold 8,310 Novo Nordisk shares in Q1 2024, an estimated $860K.
  • TimesSquare Capital Management first reported a position in Novo Nordisk in Q3 2022 and held it in 6 quarters.
  • TimesSquare Capital Management's Novo Nordisk position peaked at $1.65M in Q1 2023.
  • 1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on TimesSquare Capital Management's 13F filing for Q1 2024, filed 7 May 2024.